Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).

Scott Williams; Ian D Davis; Christopher Sweeney; Martin R Stockler; Andrew James Martin; Wendy Hague; Xanthi Coskinas; Sonia Yip; Emily Tu; Nicola Jane Lawrence; Namrata Nayar; Ray McDermott; Paul Kelly; Olwyn Deignan; Simon Hughes; Valerie Fonteyne; Bertrand F Tombal; Paul L Nguyen

Conference Proceedings

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).

Scott Williams, Ian D Davis, Christopher Sweeney, Martin R Stockler, Andrew James Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, Nicola Jane Lawrence, Namrata Nayar, Ray McDermott, Paul Kelly, Olwyn Deignan, Simon Hughes, Valerie Fonteyne, Bertrand F Tombal, Paul L Nguyen

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.2018.36.6_suppl.TPS156

Abstract

TPS156 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide improves overall survival (OS) in castration-resistant, metastatic prostate cancer. We hypothesized that the addition of enzalutamide to adjuvant ADT and RT will improve outcomes. The aim is to determine the effects of enzalutamide versus a conventional non-steroidal anti-androgen (NSAA) as part of neoadjuvant and adjuvant ADT in men undergoing RT for high risk, localized PC. Methods: DESIGN: Open label, randomised, phase 3 trial including ANZ, USA, UK, Ireland and Europe. ENDPOINTS: OS (primary), cause-sp..

View full abstract